Healthcare stocks have been the talk of the town in Q3, with several companies delivering impressive results. In this blog post, we’ll take a closer look at the performance of General Electric Company (GEHC), Bio-Techne Corporation (BBNX), and ICON Public Limited Company (ICLR), highlighting their revenue growth, margin expansion, and guidance revisions.

GEHC: 3Q Ahead and Guide Raised

General Electric Company (GEHC) delivered a strong quarter, with revenues of $5.5 billion, exceeding the consensus estimate of $5.35 billion. The company witnessed organic revenue growth of 6.2%, significantly higher than the 3.5% consensus estimate. GEHC also reported a 4% increase in organic orders, with a book-to-bill ratio of 1.03x.

The company’s earnings per share (EPS) of $1.34 surpassed the consensus estimate of $1.20, and the guidance was raised to approximately 4% organic growth and EPS of $4.95 to $5.05, which is at the high end of the previous guidance range.

BBNX: Better DME vs. Lighter Pharmacy Channel Revs

Bio-Techne Corporation (BBNX) reported third-quarter revenues of $35.5 million, marginally higher than the consensus estimate of $34.7 million. The company saw better demand for its Drug Development and Enablement (DDE) segment, offsetting a lighter performance in the Pharmacy Benefit Plan (PBP) channel.

BBNX withdrew its 510(k) application for 3D Intelligence after recent interactions with the Food and Drug Administration (FDA), and the company expects to provide additional simulator validation data in mid-fourth quarter 2026. The company now anticipates 2026 revenues in the range of $124 million to $126 million, reflecting a potential revenue deferral impact of up to $8.5 million from prospective iLet users choosing to await the launch of Mint.

ICLR: 3Q Strong Book-to-Bill and Guide Raised

ICON Public Limited Company (ICLR) delivered a strong quarter, with revenues of $1.73 billion, above the consensus estimate of $1.71 billion. The company reported an operating margin of 13.5%, significantly higher than the 11.7% consensus estimate.

ICLR’s earnings per share (EPS) of $0.70 exceeded the consensus estimate of $0.54, and the guidance was raised to approximately 2% revenue growth and EPS of $0.70 to $0.75.